This document has not been cited yet.

1. Adena M, Houltram J, Mulligan SP, Todd C, Malanos G. Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse. Pharmacoeconomics. 2014;32(2):193–207.
   Paper not yet in RePEc: Add citation now
   
2. Ara R, Wailoo A. NICE DSU technical support document 12: the use of health state utility values in decision models. 2011 (5 February 2014); Available from http://www.nicedsu.org.uk/TSD12%20Utilities%20in%20modelling%20 FINAL.pdf .
   Paper not yet in RePEc: Add citation now
   
3. Badoux XC, Keating MJ, Wang X, O’Brien SM, Ferrajoli A, Faderl S, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011;117(11):3016–24.
   Paper not yet in RePEc: Add citation now
   
4. Beusterien KM, Davies J, Leach M, Meiklejohn D, Grinspan JL, O’Toole A, et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes. 2010;8(50):1477–7525.
   Paper not yet in RePEc: Add citation now
   
5. Bottcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(9):980–8.
   Paper not yet in RePEc: Add citation now
   
6. Brazier J, Deverill M, Green C. A review of the use of health status measures in economic evaluation. J Health Serv Res Policy. 1999;4(3):174–84.
   Paper not yet in RePEc: Add citation now
   

7. Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15(12):1295–310.

8. Brenner H, Gondos A, Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood. 2008;111(10):4916–21.
   Paper not yet in RePEc: Add citation now
   
9. Canadian Agency for Drugs and Technologies in Health (CADTH). Common drug review. (5 February 2014); Available from http://www.cadth.ca/en/products/cdr .
   Paper not yet in RePEc: Add citation now
   
10. Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices—overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value Health. 2012;15(6):796–803.
    Paper not yet in RePEc: Add citation now
    
11. Caro JJ, Möller J, Getsios D. Discrete event simulation: the preferred technique for health economic evaluations? Value Health. 2010;13(8):1056–60.
    Paper not yet in RePEc: Add citation now
    
12. Catovsky D, Richards S, Hillmen P. Early results from LRF CLL4: A UK multicenter randomized trial. ASH Annual Meeting Abstracts, 2005. p. 716.
    Paper not yet in RePEc: Add citation now
    
13. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists’ Collaborative Group. J Natl Cancer Inst. 1999;91(10):861–8.
    Paper not yet in RePEc: Add citation now
    
14. Dervaux B, Lenne X, Theis D, D’Alche-Gautier M-J, Rufat P, Cazin B, et al. Cost effectiveness of oral fludarabine in chronic lymphocytic leukaemia: the French case. J Med Econ. 2007;10(4):339–54.
    Paper not yet in RePEc: Add citation now
    
15. Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, et al. Chlorambucil in indolent chronic lymphocytic leukemia. N Eng J Med. 1998;338(21):1506–14.
    Paper not yet in RePEc: Add citation now
    
16. Doorduijn J, Buijt I, Holt B, Steijaert M, Uyl-de Groot C, Sonneveld P. Self-reported quality of life in elderly patients with aggressive non-Hodgkin’s lymphoma treated with CHOP chemotherapy. Eur J Haematol. 2005;75(2):116–23.
    Paper not yet in RePEc: Add citation now
    
17. Eddy D. Bringing health economic modeling to the 21st century. Value Health. 2006;9(3):168–78.
    Paper not yet in RePEc: Add citation now
    
18. Else M, Smith AG, Cocks K, Richards SM, Crofts S, Wade R, et al. Patients’ experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial. Br J Haematol. 2008;143(5):690–7.
    Paper not yet in RePEc: Add citation now
    
19. Ferguson J, Tolley K, Gilmour L, Priaulx J. PCN79 Health state preference study mapping the change over the course of the disease process in chronic lymphocytic leukemia (CLL). Value Health. 2008;11(6):A485.
    Paper not yet in RePEc: Add citation now
    
20. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Eng J Med. 2014;370(12):1101–10 Epub 2014/01/10.
    Paper not yet in RePEc: Add citation now
    
21. Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(11):2138–46.
    Paper not yet in RePEc: Add citation now
    
22. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–56.
    Paper not yet in RePEc: Add citation now
    
23. Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood. 2013;122(23):3723–34.
    Paper not yet in RePEc: Add citation now
    
24. Hancock S, Wake B, Hyde C. Fludarabine as first line therapy for CLL. West Midlands Health Technology Assessment Collaboration report, 2003.
    Paper not yet in RePEc: Add citation now
    
25. Holzner B, Kemmler G, Sperner-Unterweger B, Kopp M, Dunser M, Margreiter R, et al. Quality of life measurement in oncology—a matter of the assessment instrument? Eur J Cancer. 2001;37(18):2349–56 Epub 2001/11/27.
    Paper not yet in RePEc: Add citation now
    
26. Hoyle M, Crathorne L, Jones-Hughes T, Stein K. Bendamustine for the first-line treatment of chronic lymphocytic leukaemia 3 (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate: a critique of the submission from Napp. University of Exeter (Report), 2010.
    Paper not yet in RePEc: Add citation now
    
27. Hoyle M, Crathorne L, Moxham T, Garside R, Hyde C. Ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK. University of Exeter (Report), 2010.
    Paper not yet in RePEc: Add citation now
    
28. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. N Eng J Med. 1988; 319(14):902–7 (Epub 1988/10/06).
    Paper not yet in RePEc: Add citation now
    

29. Ishak KJ, Kreif N, Benedict A, Muszbek N. Overview of parametric survival analysis for health-economic applications. Pharmacoeconomics. 2013;31(8):663–75.

30. Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(26):4378–84.
    Paper not yet in RePEc: Add citation now
    
31. Kongnakorn T, Sterchele JA, Salvador CG, Getsios D, Mwamburi M. Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis. Clinicoecon Outcomes Res. 2014;6:141–9.
    Paper not yet in RePEc: Add citation now
    
32. Latimer NR. Survival analysis for economic evaluations alongside clinical trials–extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33(6):743–54.
    Paper not yet in RePEc: Add citation now
    
33. Main C, Pitt M, Moxham T, Stein K. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche. Health Technol Assess. 2010;14(Suppl. 2):27–32.
    Paper not yet in RePEc: Add citation now
    
34. Maloum K, Settegrana C, Chapiro E, Cazin B, Lepretre S, Delmer A, et al. IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide. Ann Hematol. 2009;88(12):1215–21.
    Paper not yet in RePEc: Add citation now
    

35. Marsh K, Xu P, Orfanos P, Benedict A, Desai K, Griebsch I. Model-based cost-effectiveness analyses for the treatment of chronic myeloid leukaemia: a review and summary of challenges. Pharmacoeconomics. 2014;7:7.

36. McKenzie L, van der Pol M. Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data. Value Health. 2009;12(1):167–71.
    Paper not yet in RePEc: Add citation now
    
37. Molica S. Progression and survival studies in early chronic lymphocytic leukemia. Blood. 1991;78(4):895–9.
    Paper not yet in RePEc: Add citation now
    
38. Montserrat E. Assessing prognosis in patients with chronic lymphocytic leukemia a quarter of a century after Rai and Binet staging systems. Ann Oncol. 2004;15(10):1450–1.
    Paper not yet in RePEc: Add citation now
    
39. Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(13):2971–9.
    Paper not yet in RePEc: Add citation now
    
40. Napp Pharmaceuticals Ltd. Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate, 2010. http://www.nice.org.uk/guidance/ta216/resources/leukaemia-lymph ocytic-bendamustine-manufacturer-submission2 .
    Paper not yet in RePEc: Add citation now
    
41. National Institute for Health and Care Excellence (NICE). Chronic lymphocytic leukaemia—ofatumumab: manufacturers submission. NICE Technology appraisal Guidance (TA202) London: National Institute for Health and Care Excellence, 2010.
    Paper not yet in RePEc: Add citation now
    
42. National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. 2013 (5 February 2014); Available from http://www.nice.org.uk/media/D45/1E/GuideToMethodsTechnologyApp raisal2013.pdf .
    Paper not yet in RePEc: Add citation now
    
43. National Institute for Health and Care Excellence (NICE). Leukaemia (lymphocytic). 2013 (5 February 2014); Available from http://www.nice.org.uk/Search.do?searchText=Leukaemia+%28lympho cytic%29&newsearch=true&x=0&y=0 .
    Paper not yet in RePEc: Add citation now
    
44. O’Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(5):1414–20.
    Paper not yet in RePEc: Add citation now
    
45. Pharmaceutical Benefits Advisory Committee (PBAC). PBAC outcomes. (5 February 2014); Available from http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetin gs/pbac-outcomes .
    Paper not yet in RePEc: Add citation now
    
46. Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care. 2004;13(3):279–87.
    Paper not yet in RePEc: Add citation now
    
47. Roche. Rituximab for the 1st line treatment of Chronic Lymphocytic Leukaemia, 2008. http://www.nice.org.uk/guidance/ta174/resources/roche-submissio n2 .
    Paper not yet in RePEc: Add citation now
    
48. Roche. Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia, 2009. http://www.nice.org.uk/guidance/ta193/resources/nice-submission -rituximab-for-the-treatment-of-relapsedrefractory-chronic-lymphocytic-leu kaemia2 .
    Paper not yet in RePEc: Add citation now
    
49. Schering. Fludarabine phosphate for the first-line treatment of Chronic Lymphocytic Leukaemia, 2006. http://www.nice.org.uk/guidance/ta119/resources/schering-health -care-ltd-submission2 .
    Paper not yet in RePEc: Add citation now
    
50. Shanafelt TD, Gunderson H, Call TG. Commentary: chronic lymphocytic leukemia—the price of progress. Oncologist. 2010;15(6):601–2.
    Paper not yet in RePEc: Add citation now
    
51. Stephens JM, Gramegna P, Laskin B, Botteman MF, Pashos CL. Chronic lymphocytic leukemia: economic burden and quality of life: literature review. Am J Ther. 2005;12(5):460–6.
    Paper not yet in RePEc: Add citation now
    
52. Tam CS, O’Brien S, Wierda W, Kantarjian H, Wen S, Do KA, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975–80.
    Paper not yet in RePEc: Add citation now
    
53. Walker S, Palmer S, Erhorn S, Brent S, Dyker A, Ferrie L, et al. Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia. Health Technol Assess. 2009;1:35–40.
    Paper not yet in RePEc: Add citation now
    
54. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Eng J Med. 1991;325(2):81–6.
    Paper not yet in RePEc: Add citation now
    
55. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(10):1749–55 Epub 2010/03/03.
    Paper not yet in RePEc: Add citation now
    
56. Wild D, Walker M, Pettengell R, Lewis G. PCN62 Utility Elicitation in patients with follicular lymphoma. Value Health J Int Soc Pharmacoecon Outcomes Res. 2006;9(6):A294.
    Paper not yet in RePEc: Add citation now
    

1. Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions. (2021). Lewis, Ruth A ; Hughes, Dyfrig ; Wilkinson, Clare ; Sutton, Alex J.
   In: PharmacoEconomics.
   RePEc:spr:pharme:v:39:y:2021:i:1:d:10.1007_s40273-020-00980-w.

   Full description at Econpapers || Download paper

2. A Framework for Developing a Model Structure of Budget Impact Analysis for New Health Care Interventions in Jordan. (2021). Massad, Eman Mohammad ; Bakir, Amir.
   In: International Journal of Economics and Financial Issues.
   RePEc:eco:journ1:2021-01-13.

   Full description at Econpapers || Download paper

3. A Systematic Review of Model-Based Economic Evaluations of Treatments for Venous Leg Ulcers. (2020). Levell, N J ; McManus, Emma ; Layer, Ashley.
   In: PharmacoEconomics - Open.
   RePEc:spr:pharmo:v:4:y:2020:i:2:d:10.1007_s41669-019-0148-x.

   Full description at Econpapers || Download paper

4. Modelling the impact of physical activity on public health: A review and critique. (2020). Candio, Paolo ; Bojke, Laura ; Meads, David ; Hill, Andrew J.
   In: Health Policy.
   RePEc:eee:hepoli:v:124:y:2020:i:10:p:1155-1164.

   Full description at Econpapers || Download paper

5. Spatial Transmission Models: A Taxonomy and Framework. (2019). Robertson, Duncan A.
   In: Risk Analysis.
   RePEc:wly:riskan:v:39:y:2019:i:1:p:225-243.

   Full description at Econpapers || Download paper

6. Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review. (2019). Newman, William G ; Wright, Stuart J ; Payne, Katherine.
   In: PharmacoEconomics.
   RePEc:spr:pharme:v:37:y:2019:i:8:d:10.1007_s40273-019-00801-9.

   Full description at Econpapers || Download paper

7. Exploring Different Strategies of Assessing the Economic Impact of Multiple Diabetes-Associated Complications and Their Interactions: A Large Claims-Based Study in Germany. (2019). Schneider, Udo ; Holle, Rolf ; Laxy, Michael ; Kahm, Katharina.
   In: PharmacoEconomics.
   RePEc:spr:pharme:v:37:y:2019:i:1:d:10.1007_s40273-018-0699-1.

   Full description at Econpapers || Download paper

8. A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments. (2019). Cranmer, Holly L ; Shields, Gemma E ; Bullement, Ash.
   In: Applied Health Economics and Health Policy.
   RePEc:spr:aphecp:v:17:y:2019:i:6:d:10.1007_s40258-019-00513-3.

   Full description at Econpapers || Download paper

9. Smoking Cessation: A Comparison of Two Model Structures. (2018). Taylor, Matthew ; Owen, Lesley ; Pennington, Becky ; Filby, Alex.
   In: PharmacoEconomics.
   RePEc:spr:pharme:v:36:y:2018:i:9:d:10.1007_s40273-018-0657-y.

   Full description at Econpapers || Download paper

10. The Use of Decision–Analytic Models in Atopic Eczema: A Systematic Review and Critical Appraisal. (2018). Sach, Tracey ; Levell, Nick ; McManus, Emma.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:36:y:2018:i:1:d:10.1007_s40273-017-0564-7.

    Full description at Econpapers || Download paper

11. Model Structuring for Economic Evaluations of New Health Technologies. (2018). Bojke, Laura ; Karnon, Jonathan ; Ali, Hossein Haji.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:36:y:2018:i:11:d:10.1007_s40273-018-0693-7.

    Full description at Econpapers || Download paper

12. Model Registration: A Call to Action. (2017). Sampson, Christopher ; Wrightson, Tim.
    In: PharmacoEconomics - Open.
    RePEc:spr:pharmo:v:1:y:2017:i:2:d:10.1007_s41669-017-0019-2.

    Full description at Econpapers || Download paper

13. Simulation Modelling in Healthcare: An Umbrella Review of Systematic Literature Reviews. (2017). Salleh, Syed ; Hughes, Ruby ; Thokala, Praveen ; Booth, Andrew ; Brennan, Alan.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:35:y:2017:i:9:d:10.1007_s40273-017-0523-3.

    Full description at Econpapers || Download paper

14. Using Parameter Constraints to Choose State Structures in Cost-Effectiveness Modelling. (2017). Welton, Nicky ; Sharples, Linda ; Thom, Howard ; Jackson, Chris.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:35:y:2017:i:9:d:10.1007_s40273-017-0501-9.

    Full description at Econpapers || Download paper

15. Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis. (2017). Shih, Ya-Chen ; Lecomte, Pascal ; Olson, Melvin ; Mullins, Daniel C ; Goto, Daisuke ; Udeze, Chukwukadibia ; Park, Yujin.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:35:y:2017:i:7:d:10.1007_s40273-017-0505-5.

    Full description at Econpapers || Download paper

16. Sourcing and Using Appropriate Health State Utility Values in Economic Models in Health Care. (2017). Brazier, John ; Azzabi-Zouraq, Ismail ; Chevrou-Severac, Helene ; Rowen, Donna ; Mukuria, Clara ; Hout, Ben ; Young, Tracey ; Peasgood, Tessa ; Paisley, Suzy ; Ara, Roberta.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:35:y:2017:i:1:d:10.1007_s40273-017-0543-z.

    Full description at Econpapers || Download paper

17. An empirical comparison of Markov cohort modeling and discrete event simulation in a capacity-constrained health care setting. (2017). Scuffham, Paul ; Comans, T A ; Standfield, L B.
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:18:y:2017:i:1:d:10.1007_s10198-015-0756-z.

    Full description at Econpapers || Download paper

18. Enabling better management of patients: discrete event simulation combined with the STAR approach. (2017). Demir, Eren ; Southern, David.
    In: Journal of the Operational Research Society.
    RePEc:pal:jorsoc:v:68:y:2017:i:5:d:10.1057_s41274-016-0029-y.

    Full description at Econpapers || Download paper

19. Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer’s Disease. (2016). Santos, Rodrigo Dos ; Hernandez, Luis ; Getsios, Denis ; Ozen, Asli .
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:34:y:2016:i:7:d:10.1007_s40273-016-0392-1.

    Full description at Econpapers || Download paper

20. Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. (2016). Wasem, Juergen ; Beutels, Philippe ; Levy-Bruhl, Daniel ; Damm, Oliver ; Ultsch, Bernhard ; Wichmann, Ole ; Bruggenjurgen, Bernd ; Knol, Mirjam ; Gerber-Grote, Andreas ; Perleth, Matthias ; Kuhlmann, Alexander ; Jit, Mark ; Postma, Maarten ; Greiner, Wolfgang ; Siebert, Uwe ; Bilcke, Joke ; Kries, Rudiger ; Salo, Heini ; Hutubessy, Raymond ; Hanquet, Germaine .
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:34:y:2016:i:3:p:227-244.

    Full description at Econpapers || Download paper

21. Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. (2016). Wasem, Juergen ; Beutels, Philippe ; Levy-Bruhl, Daniel ; Damm, Oliver ; Ultsch, Bernhard ; Wichmann, Ole ; Bruggenjurgen, Bernd ; Knol, Mirjam ; Gerber-Grote, Andreas ; Perleth, Matthias ; Kuhlmann, Alexander ; Jit, Mark ; Postma, Maarten ; Greiner, Wolfgang ; Siebert, Uwe ; Bilcke, Joke ; Kries, Rudiger ; Salo, Heini ; Hutubessy, Raymond ; Hanquet, Germaine .
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:34:y:2016:i:3:d:10.1007_s40273-015-0335-2.

    Full description at Econpapers || Download paper

22. Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment. (2016). Card, Timothy ; West, Joe ; Canavan, Caroline.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:34:y:2016:i:2:p:181-194.

    Full description at Econpapers || Download paper

23. Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment. (2016). Card, Timothy ; West, Joe ; Canavan, Caroline.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:34:y:2016:i:2:d:10.1007_s40273-015-0339-y.

    Full description at Econpapers || Download paper

24. Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations. (2016). Rogowski, Wolf H ; Payne, Katherine ; Iglesias, Cynthia P ; Thompson, Alexander.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:34:y:2016:i:11:d:10.1007_s40273-016-0425-9.

    Full description at Econpapers || Download paper

25. A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure. (2016). Tomini, F ; Prinzen, F.
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:17:y:2016:i:9:d:10.1007_s10198-015-0752-3.

    Full description at Econpapers || Download paper

26. Calibrating Parameters for Microsimulation Disease Models. (2016). Lansdorp-Vogelaar, Iris ; de Koning, Harry J ; van Hees, Frank ; Steyerberg, Ewout W ; van der Steen, Alex ; Kroep, Sonja ; van Ballegooijen, Marjolein ; van Rosmalen, Joost.
    In: Medical Decision Making.
    RePEc:sae:medema:v:36:y:2016:i:5:p:652-665.

    Full description at Econpapers || Download paper

27. Incorporating Psychological Predictors of Treatment Response into Health Economic Simulation Models. (2015). Basarir, Hasan ; Kruger, Jen ; Cooke, Debbie ; Pollard, Daniel ; Brennan, Alan ; Heller, Simon ; Bond, Rod ; Thokala, Praveen ; Clark, Marie.
    In: Medical Decision Making.
    RePEc:sae:medema:v:35:y:2015:i:7:p:872-887.

    Full description at Econpapers || Download paper

28. Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Lymphocytic Leukaemia: A Review of Methods to Model Disease Outcomes and Estimate Utility. (2014). Xu, Peng ; Orfanos, Panagiotis ; Marsh, Kevin ; Gordon, James ; Griebsch, Ingolf.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:32:y:2014:i:10:p:981-993.

    Full description at Econpapers || Download paper

29. Cost-effectiveness of primary prevention of paediatric asthma: a decision-analytic model. (2014). Severens, Johan ; Knottnerus, J. ; Ramos, G. ; Dompeling, Edward ; Asselt, Antoinette ; Maas, Tanja ; Kuiper, Sandra ; Schayck, Onno .
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:15:y:2014:i:8:p:869-883.

    Full description at Econpapers || Download paper

30. A Systematic and Critical Review of Model-Based Economic Evaluations of Pharmacotherapeutics in Patients with Bipolar Disorder. (2014). Mohiuddin, Syed.
    In: Applied Health Economics and Health Policy.
    RePEc:spr:aphecp:v:12:y:2014:i:4:p:359-372.

    Full description at Econpapers || Download paper

31. Combining discrete-event simulation and system dynamics in a healthcare setting: A composite model for Chlamydia infection. (2014). Harindra, V. ; Brailsford, S. C. ; Harper, P. R. ; Viana, J..
    In: European Journal of Operational Research.
    RePEc:eee:ejores:v:237:y:2014:i:1:p:196-206.

    Full description at Econpapers || Download paper

32. Improving Clinical Reality in Chronic Obstructive Pulmonary Disease Economic Modelling. (2013). Gray, Alastair ; Fonseca, Tiago ; Baldwin, Michael ; Mungapen, Laura ; Price, David ; Asukai, Yumi.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:31:y:2013:i:2:p:151-161.

    Full description at Econpapers || Download paper

33. Improving Health Outcomes Through Better Capacity Allocation in a Community-Based Chronic Care Model. (2013). Jiang, Tingting ; Samuelson, Stephen ; Iravani, Seyed ; Deo, Sarang ; Smilowitz, Karen.
    In: Operations Research.
    RePEc:inm:oropre:v:61:y:2013:i:6:p:1277-1294.

    Full description at Econpapers || Download paper

34. Economic implications of poor access to antenatal care in rural and remote Western Australian Aboriginal communities: An individual sampling model of pregnancy. (2013). Simmer, Karen ; Newnham, John P. ; Cannon, Jeffrey W. ; Hornbuckle, Janet ; Doherty, Dorota A. ; Larson, Ann ; Mueller, Ute A..
    In: European Journal of Operational Research.
    RePEc:eee:ejores:v:226:y:2013:i:2:p:313-324.

    Full description at Econpapers || Download paper

35. Modeling Using Discrete Event Simulation. (2012). Karnon, Jonathan ; Mar, Javier ; Stahl, James ; Caro, Jaime J ; Brennan, Alan ; Mller, Jrgen.
    In: Medical Decision Making.
    RePEc:sae:medema:v:32:y:2012:i:5:p:701-711.

    Full description at Econpapers || Download paper

36. Modeling Good Research Practices€”Overview. (2012). Siebert, Uwe ; Kuntz, Karen M ; Caro, Jaime J ; Briggs, Andrew H.
    In: Medical Decision Making.
    RePEc:sae:medema:v:32:y:2012:i:5:p:667-677.

    Full description at Econpapers || Download paper

37. Future Impact of Various Interventions on the Burden of COPD in Canada: A Dynamic Population Model. (2012). Fitzgerald, Mark J ; Lynd, Larry D ; Sin, Don ; Marra, Carlo A ; McManus, Bruce ; Sadatsafavi, Mohsen ; Najafzadeh, Mehdi.
    In: PLOS ONE.
    RePEc:plo:pone00:0046746.

    Full description at Econpapers || Download paper

38. Resource planning for ambulance services in mass casualty incidents: a DES-based policy model. (2012). Schaffhauser-Linzatti, Michaela ; Rauner, Marion ; Niessner, Helmut.
    In: Health Care Management Science.
    RePEc:kap:hcarem:v:15:y:2012:i:3:p:254-269.

    Full description at Econpapers || Download paper

39. What happens to value of information measures as the number of decision options increases?. (2011). Barton, Pelham.
    In: Health Economics.
    RePEc:wly:hlthec:v:20:y:2011:i:7:p:853-863.

    Full description at Econpapers || Download paper

40. A Framework for Addressing Structural Uncertainty in Decision Models. (2011). Thompson, Simon G ; Sharples, Linda D ; Bojke, Laura ; Claxton, Karl ; Jackson, Christopher H.
    In: Medical Decision Making.
    RePEc:sae:medema:v:31:y:2011:i:4:p:662-674.

    Full description at Econpapers || Download paper

41. Dynamic versus static models in cost‐effectiveness analyses of anti‐viral drug therapy to mitigate an influenza pandemic. (2010). Mylius, Sido D. ; Wallinga, Jacco ; Lugner, Anna K..
    In: Health Economics.
    RePEc:wly:hlthec:v:19:y:2010:i:5:p:518-531.

    Full description at Econpapers || Download paper

42. Hospital management games: a taxonomy and extensive review. (2010). Schwarz, Sigrun ; Kraus, Markus ; Rauner, Marion.
    In: Central European Journal of Operations Research.
    RePEc:spr:cejnor:v:18:y:2010:i:4:p:567-591.

    Full description at Econpapers || Download paper

43. Reducing access times for an endoscopy department by an iterative combination of computer simulation and Linear Programming. (2010). Elkhuizen, S. ; Joustra, P. ; Fockens, P. ; Wit, J. ; Overbeek, B. ; Struben, V..
    In: Health Care Management Science.
    RePEc:kap:hcarem:v:13:y:2010:i:1:p:17-26.

    Full description at Econpapers || Download paper

44. Dynamic Policy Modeling for Chronic Diseases: Metaheuristic-Based Identification of Pareto-Optimal Screening Strategies. (2010). Gutjahr, Walter J ; Rauner, Marion S ; Heidenberger, Kurt ; Pasia, Joseph ; Wagner, Joachim.
    In: Operations Research.
    RePEc:inm:oropre:v:58:y:2010:i:5:p:1269-1286.

    Full description at Econpapers || Download paper

45. Simulation sample sizes for Monte Carlo partial EVPI calculations. (2010). Tappenden, Paul ; Chilcott, Jim ; Oakley, Jeremy E. ; Brennan, Alan.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:29:y:2010:i:3:p:468-477.

    Full description at Econpapers || Download paper

46. Simulation or cohort models? Continuous time simulation and discretized Markov models to estimate cost-effectiveness. (2010). Soares, Marta ; L Canto e Castro, .
    In: Working Papers.
    RePEc:chy:respap:56cherp.

    Full description at Econpapers || Download paper

47. The cost-effectiveness of surgical instrument management policies to reduce the risk of vCJD transmission to humans. (2009). Chick, S E ; Stevenson, M D ; Chalkidou, K ; Oakley, J E.
    In: Journal of the Operational Research Society.
    RePEc:pal:jorsoc:v:60:y:2009:i:4:d:10.1057_palgrave.jors.2602580.

    Full description at Econpapers || Download paper

48. A tutorial on discrete-event simulation for health policy design and decision making: Optimizing pediatric ultrasound screening for hip dysplasia as an illustration. (2009). Sakkers, Ralph J. B., ; Ramwadhdoebe, Sabrina ; Stahl, James E. ; Buskens, Erik.
    In: Health Policy.
    RePEc:eee:hepoli:v:93:y:2009:i:2-3:p:143-150.

    Full description at Econpapers || Download paper

49. Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA. (2007). Stevenson, Matt ; Madan, Jason ; O'Hagan, Anthony.
    In: Health Economics.
    RePEc:wly:hlthec:v:16:y:2007:i:10:p:1009-1023:a.

    Full description at Econpapers || Download paper

50. Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA. (2007). Stevenson, Matt ; Madan, Jason ; O'Hagan, Anthony.
    In: Health Economics.
    RePEc:wly:hlthec:v:16:y:2007:i:10:p:1009-1023.

    Full description at Econpapers || Download paper

Report date: 2025-10-01 10:09:59 || Missing content? Let us know